Ignite Creation Date:
2024-05-06 @ 1:26 PM
Last Modification Date:
2024-10-26 @ 1:14 PM
Study NCT ID:
NCT04027309
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2023-06-15
First Post:
2019-07-18
Brief Title:
A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy
Sponsor:
Stichting Hemato-Oncologie voor Volwassenen Nederland
Organization:
Stichting Hemato-Oncologie voor Volwassenen Nederland
Organization Data
Organization:
Stichting Hemato-Oncologie voor Volwassenen Nederland
Class:
OTHER
Study ID:
HO156
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Stichting Hemato-Oncologie voor Volwassenen Nederland
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Astellas Pharma Global Development Inc | INDUSTRY |
| Deutsch-Österreichische Studiengruppe Akute Myeloische Leukämie AMLSG | UNKNOWN |